KR960029319A - 4-아미노벤조일구아니딘 유도체 - Google Patents

4-아미노벤조일구아니딘 유도체 Download PDF

Info

Publication number
KR960029319A
KR960029319A KR1019960002014A KR19960002014A KR960029319A KR 960029319 A KR960029319 A KR 960029319A KR 1019960002014 A KR1019960002014 A KR 1019960002014A KR 19960002014 A KR19960002014 A KR 19960002014A KR 960029319 A KR960029319 A KR 960029319A
Authority
KR
South Korea
Prior art keywords
general formula
group
diaminomethylene
physiologically acceptable
methylsulfonylbenzoamide
Prior art date
Application number
KR1019960002014A
Other languages
English (en)
Other versions
KR100521853B1 (ko
Inventor
게릭케 롤프
바움가르쓰 만프레트
바이에르 노르베르트
밍크 클라우스-오토
Original Assignee
크리스찬 플뢰미히
메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스찬 플뢰미히, 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁 filed Critical 크리스찬 플뢰미히
Publication of KR960029319A publication Critical patent/KR960029319A/ko
Application granted granted Critical
Publication of KR100521853B1 publication Critical patent/KR100521853B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Abstract

본 발명은 하기 일반식(Ⅰ)으로 표시되는 4-아미노벤조일구아니딘 유도체 및 이의 생리학적으로 허용 가능한 염을 제공한다.
(Ⅰ)
(단, 상기 식에서, R1은 A, CF3, CH2F, CHF2또는 C2F5이고,R2및 R3는 각기 독립적으로 H, A, 탄소수가 3 내지 7인 시클로알킬기, Rh 또는 Het이고, R2및 R3는 함께 결합하여 탄소수가 4 또는 5인 알킬렌기이고, Het는 N 또는 C를 통하여 결합되는 N, O 및/또는 S원자수가 1~4인 단일고리형 또는 두고리형의 포화, 불포화 또는방향성 헤테로고리형기이고, 이 기는 Hal, CF3, A, OH, OA, SH, SA, NH2, NHA, NA2, CN, NO2및/또는 카르보닐산소로 일-, 이- 또는 삼치환되거나 또는 비치환된 기이며, A는 탄소수가 1 내지 6인 알킬기이며, Het은 F, Cl, Br 또는 I이고, Ph는 A, OA, NH2, NHA, NA2, F, Cl, Br 및/또는 CF3로 일-, 이- 또는 삼치환되거나 또는 비치환된 페닐이다).
본 발명의 화합물은 세포내 Na+/H+상호수송기의 억제제로서 작용하고 항부정맥 특성을 나타낸다.

Description

4-아미노벤조일구아니딘 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 일반식(Ⅰ)으로 표시되는 4-아미노벤조일구아니딘 유도체 및 이의 생리학적으로 허용 가능한 염.
    (Ⅰ)
    (단, 상기 식에서, R1은 A, CF3, CH2F, CHF2또는 C2F|5이고,R2및 R3는 각기 독립적으로 H, A, 탄소수가 3 내지 7인 시클로알킬기, Rh 또는 Het이고, R2및 R3는 함께 결합하여 탄소수가 4 또는 5인 알킬렌기이고, Het는 N 또는 C를 통하여 결합되는 N, O 및/또는 S원자수가 1~4인 단일고리형 또는 두고리형의 포화, 불포화 또는 방향성 헤테로고리형기이고, 이 기는 Hal, CF3, A, OH, OA, SH, SA, NH2, NHA, NA2, CN, NO2및/또는 카르보닐산소로 일-, 이- 또는 삼치환되거나 또는 비치환된 기이며, A는 탄소수가 1 내지 6인 알킬기이며, Het은 F, Cl, Br 또는 I이고, Ph는 A, OA, NH2, NHA, NA2, F, Cl, Br 및/또는 CF3로 일-, 이- 또는 삼치환되거나 또는 비치환된 페닐이다).
  2. 제1항에 있어서, 상기한 일반식(Ⅰ)의 화합물이 다음 화합물(a) 내지 (g)인 것을 특징으로 하는 화합물 및 이들의 생리학적으로 허용 가능한 염 : (a) N-디아미노메틸렌-2-에틸-4-피페리디노-5-메틸술포닐벤조아미드; (b) N-디아미노메틸렌-2-메틸-4-피페리디노-5-메틸술포닐벤조아미드; (c)N-디아미노메틸렌-2-메틸-4-N,N-디이소프로필아미노-5-메틸술포닐벤조아미드; (d) N-디아미노메틸렌-2-메틸-4-페닐아미노-5-메틸술포닐벤조아미드; (e) N-디아미노메틸렌-2-메틸-4-(2-피리미딘일아미노)-5-메틸술포닐벤조아미드; (f) N-디아미노메틸렌-2-메틸-4-(3-클로로페닐아미노)-5-메틸술포닐벤조아미드; (g) N-디아미노메틸렌-2-메틸-4-(N′,N′-디이소프로필아미노)-5-메틸술포닐벤조아미드.
  3. 제1항에 따른 일반식(Ⅰ)으로 표시되는 아미노벤조일구아니딘 유도체 및 이들의 염중 하나를 제조하는 방법에 있어서, 하기 일반식(Ⅱ)으로 표시되는 화합물을 구아니딘과 반응시키거나, 또는 하기 일반식(Ⅲ)으로 표시되는 벤조일구아니딘을 하기 일반식(Ⅳ)으로 표시되는 화합물과 반응시키거나, 또는 하나 이상의 수소원자 대신에 하나 이상의 환원성 기 및/또는 하나 이상의 추가의 C-C 및/또는 C-N결합을 가지며 그밖에는 일반식(Ⅰ)과 일치하는 화합물을 환원제로 치리하거나, 또는 하나 이상의 수소원자 대신에 하나 이상의 가용매분해성기를 가지며 그밖에는 일반식(Ⅰ)과 일치하는 화합물을 가용매성분해제로 처리하거나 및/또는 생성된 일반식(Ⅰ)의 염기를 산으로 처리함으로써 이의 염중의 하나로 전환시키는 것을 특징으로 하는 제조방법.
    (Ⅱ)
    (Ⅲ)
    R3-R2-N-D (Ⅳ)
    (단, 상기 식에서, R1, R2, R3및 A는 상기에서 정의된 바와 같고, Q는 Cl, Br, OA, O-CO-A, O-CO-Ph, OH, 또는 기타 반응적으로 에스테르화된 OH기 또는 친핵적으로 쉽게 치환될 수 있는 이탈기이고, R4는 F, Cl, Br, I 또는 기타 적합한 이탈기이다).
  4. 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물 및/또는 이의 생리학적으로 허용 가능한 염중의 하나를 1종 이상의 고체, 액체 또는 반액체 부형제 또는 보조제와 함께 적합한 투여 형태로 만드는 것을 특징으로 하는 약제학적 제형의 제조방법.
  5. 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물 1종 이상 및/또는 이의 생리학적으로 허용 가능한 염중의 하나를 함유하는 것을 특징으로 하는 약제학적 제형.
  6. 질병 치료용 약물의 제조에 사용되는 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물 또는 이의 생리학적으로 허용 가능한 염.
  7. 질병의 조절에 사용되는 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물 또는 이의 생리학적으로 허용 가능한 염.
  8. 부정맥중, 협심증 및 경색중의 치료, 또는 상기 질병의 예방치료용 약물의 제조에 사용되는 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960002014A 1995-01-28 1996-01-27 4-아미노벤조일구아니딘유도체 KR100521853B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19502644.6 1995-01-28
DE19502644A DE19502644A1 (de) 1995-01-28 1995-01-28 4-Amino-benzoylguanidin-Derivate

Publications (2)

Publication Number Publication Date
KR960029319A true KR960029319A (ko) 1996-08-17
KR100521853B1 KR100521853B1 (ko) 2006-06-16

Family

ID=7752517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960002014A KR100521853B1 (ko) 1995-01-28 1996-01-27 4-아미노벤조일구아니딘유도체

Country Status (28)

Country Link
US (1) US5739142A (ko)
EP (1) EP0723963B1 (ko)
JP (1) JP3770946B2 (ko)
KR (1) KR100521853B1 (ko)
CN (1) CN1057999C (ko)
AR (1) AR002273A1 (ko)
AT (1) ATE202093T1 (ko)
AU (1) AU705632B2 (ko)
BR (1) BR9600217A (ko)
CA (1) CA2168192C (ko)
CO (1) CO4700428A1 (ko)
CZ (1) CZ289922B6 (ko)
DE (2) DE19502644A1 (ko)
DK (1) DK0723963T3 (ko)
ES (1) ES2158153T3 (ko)
FI (1) FI960376A (ko)
GR (1) GR3036572T3 (ko)
HU (1) HUP9600173A3 (ko)
NO (1) NO305793B1 (ko)
PL (1) PL182219B1 (ko)
PT (1) PT723963E (ko)
RU (1) RU2160728C2 (ko)
SI (1) SI0723963T1 (ko)
SK (1) SK281198B6 (ko)
TR (1) TR199600064A2 (ko)
TW (1) TW325463B (ko)
UA (1) UA56983C2 (ko)
ZA (1) ZA96629B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4328352A1 (de) * 1993-08-24 1995-03-02 Hoechst Ag Substituierte N,N'-Di-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
DE69919349T2 (de) * 1998-03-23 2005-01-13 Aventis Pharmaceuticals Inc. Piperidinyl- und n-amidinopiperidinyl-derivate
EP1131064A2 (en) * 1998-11-26 2001-09-12 MERCK PATENT GmbH Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
DE19859727A1 (de) 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
DE10023405A1 (de) * 2000-05-12 2001-11-15 Merck Patent Gmbh Verfahren zur Herstellung von Sulfonyl-benzoylguanidinum-Salzen
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
DE102005030400A1 (de) * 2005-06-27 2006-12-28 Archimica Gmbh Verfahren zur Herstellung von Arylaminen, Arylethern und Arylthioethern

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
DE59305042D1 (de) * 1992-09-22 1997-02-20 Hoechst Ag Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
DE4328869A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
US5739142A (en) 1998-04-14
CZ289922B6 (cs) 2002-04-17
AR002273A1 (es) 1998-03-11
GR3036572T3 (en) 2001-12-31
SI0723963T1 (en) 2002-08-31
ZA96629B (en) 1996-10-24
JPH08269001A (ja) 1996-10-15
NO960353D0 (no) 1996-01-26
JP3770946B2 (ja) 2006-04-26
DK0723963T3 (da) 2001-09-24
TR199600064A2 (tr) 1996-08-21
SK12296A3 (en) 1996-09-04
NO960353L (no) 1996-07-29
CN1057999C (zh) 2000-11-01
EP0723963A1 (de) 1996-07-31
FI960376A0 (fi) 1996-01-26
CA2168192C (en) 2008-07-29
ATE202093T1 (de) 2001-06-15
BR9600217A (pt) 1998-01-06
HUP9600173A2 (en) 1997-01-28
UA56983C2 (uk) 2003-06-16
PL312490A1 (en) 1996-08-05
CO4700428A1 (es) 1998-12-29
CA2168192A1 (en) 1996-07-29
NO305793B1 (no) 1999-07-26
CN1138575A (zh) 1996-12-25
ES2158153T3 (es) 2001-09-01
AU705632B2 (en) 1999-05-27
TW325463B (en) 1998-01-21
SK281198B6 (sk) 2001-01-18
HUP9600173A3 (en) 1998-07-28
EP0723963B1 (de) 2001-06-13
FI960376A (fi) 1996-07-29
RU2160728C2 (ru) 2000-12-20
DE19502644A1 (de) 1996-08-01
DE59607054D1 (de) 2001-07-19
AU4211296A (en) 1996-08-08
CZ25296A3 (en) 1997-03-12
KR100521853B1 (ko) 2006-06-16
PT723963E (pt) 2001-11-30
PL182219B1 (pl) 2001-11-30

Similar Documents

Publication Publication Date Title
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
KR940703806A (ko) 20-메틸-치환된 비타민 D 유도체 (20-Methyl-Substituted Vitamin D Derivatives)
KR890011601A (ko) (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
KR950000728A (ko) 포스포네이트 뉴클레오티드 에스테르 유도체
KR900006318A (ko) 피페리디닐 벤즈이미다졸
DE3271269D1 (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
AU2095092A (en) New arylethylamine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
KR900003151A (ko) 화합물
KR890002060A (ko) 옥사졸리디논 화합물
HUT57773A (en) Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds
KR960029319A (ko) 4-아미노벤조일구아니딘 유도체
KR910006309A (ko) 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제
KR960007540A (ko) 아릴벤조일구아니딘 유도체
NO834884L (no) Fremgangsmaate for fremstilling av farmakologisk aktive nitroalifatiske forbindelser
KR940003953A (ko) 1. 4-벤조디옥산 유도체
KR960041154A (ko) 플루오르 함유 벤조일구아니딘 유도체
KR970706251A (ko) 항종양제 및 항바이러스제로서의 비스-(2-할로에틸)아미노페닐 치환된 디스타마이신 유도체(Bis-(2-haloethyl)aminophenyl substituted distamycin derivatives as antitumor and antiviral agents)
ATE110721T1 (de) 2-alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische zusammensetzungen.
KR960031442A (ko) 페닐시클로헥실카르복스아미드의 용도
KR910016691A (ko) 신규한 치환된-아민 화합물 및 그의 제조방법
ES2039719T3 (es) Procedimiento para preparar un agente terapeutico para el tratamiento de la enfermedad de ulcera peptica.
WO2006034327A1 (en) Medicinal disulfide salts

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040421

Effective date: 20050729

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee